Department of Colorectal Surgery, Fujian Medical University Union Hospital, Fuzhou, Fujian, PR China.
Department of Pathology, Fujian Medical University Union Hospital, Fuzhou, Fujian, PR China.
Eur J Surg Oncol. 2019 Jul;45(7):1225-1231. doi: 10.1016/j.ejso.2019.03.005. Epub 2019 Mar 9.
To evaluate the pattern of tumor relapse of pathological complete response (pCR) patients with locally advanced rectal cancer (LARC) following neoadjuvant chemoradiotherapy (nCRT) and total mesorectal excision (TME), and to identify predictive factors of distant metastasis in pCR patients after nCRT.
This was a retrospective analysis of 118 LARC patients who achieved a pCR following nCRT and TME from 2008 to 2015. Clinicopathological and therapeutic parameters were evaluated as possible predictors of distant metastasis-free survival (DMFS), and COX regression analysis was performed.
After a median follow-up of 57 months, the 5-year overall and disease-free survival rates were 94.7% and 88.1%, respectively. Overall, 6 patients (5.1%) died, no local recurrence occurred, 13 patients (11%) developed distant metastases, including lung (n = 5), liver (n = 2), bone (n = 3), lung and brain (n = 1), peritoneal (n = 1), and spleen (n = 1) metastasis. On univariate analysis, tumor distance from the anal verge (HR = 0.706, P = 0.039), acellular mucin pools (HR = 6.687, P = 0.002), and MUC1 expression (HR = 8.280, P < 0.001) were independently associated with DMFS. COX regression demonstrated that MUC1 expression (HR = 3.812, P = 0.041) remained to be an independent predictor of DMFS in pCR patients.
Distant metastasis still remained a major concern in pCR patients following nCRT and TME. Tumor distance from the anal verge, acellular mucin pools, and MUC1 expression were associated with distant metastasis in patients with pCR. MUC1 staining remained to be an independent risk factor for DMFS. Such information could facilitate treatment decision in these patients, such as adjuvant chemotherapy and follow-up.
评估接受新辅助放化疗(nCRT)和全直肠系膜切除术(TME)后病理完全缓解(pCR)的局部进展期直肠癌(LARC)患者的肿瘤复发模式,并确定 nCRT 后 pCR 患者发生远处转移的预测因素。
这是一项回顾性分析,纳入了 2008 年至 2015 年间 118 例接受 nCRT 和 TME 后达到 pCR 的 LARC 患者。评估了临床病理和治疗参数作为无远处转移生存(DMFS)的可能预测因素,并进行 COX 回归分析。
中位随访 57 个月后,患者 5 年总生存率和无病生存率分别为 94.7%和 88.1%。总体而言,有 6 例(5.1%)患者死亡,无局部复发,13 例(11%)患者发生远处转移,包括肺(n=5)、肝(n=2)、骨(n=3)、肺和脑(n=1)、腹膜(n=1)和脾(n=1)转移。单因素分析显示,肿瘤距肛缘距离(HR=0.706,P=0.039)、无细胞黏液池(HR=6.687,P=0.002)和 MUC1 表达(HR=8.280,P<0.001)与 DMFS 独立相关。COX 回归分析表明,MUC1 表达(HR=3.812,P=0.041)仍然是 pCR 患者 DMFS 的独立预测因素。
在接受 nCRT 和 TME 治疗后,pCR 患者仍存在远处转移的主要问题。肿瘤距肛缘距离、无细胞黏液池和 MUC1 表达与 pCR 患者的远处转移有关。MUC1 染色仍然是 DMFS 的独立危险因素。这些信息可以为这些患者的治疗决策提供帮助,如辅助化疗和随访。